Zenlabs Ethica Limited
Zenlabs Ethica Limited (ZENLABS.BO) Stock Competitors & Peer Comparison
See (ZENLABS.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZENLABS.BO | ₹21.06 | +0.14% | 137.1M | -7.42 | -₹2.84 | N/A |
| MEDPLUS.BO | ₹836.20 | +0.75% | 100.3B | 48.53 | ₹17.23 | N/A |
| MEDPLUS.NS | ₹835.20 | +0.73% | 100.2B | 48.36 | ₹17.27 | N/A |
| GUJTHEM.BO | ₹334.70 | -0.12% | 36.5B | 76.59 | ₹4.37 | +0.20% |
| SHUKRAPHAR.BO | ₹35.92 | -4.06% | 15.7B | -179.60 | -₹0.20 | +0.06% |
| KPL.BO | ₹1,411.40 | -0.93% | 14.6B | 25.86 | ₹54.57 | N/A |
| SASTASUNDR.BO | ₹287.25 | +0.14% | 9.1B | 35.12 | ₹8.18 | N/A |
| SASTASUNDR.NS | ₹286.75 | +0.65% | 9.1B | 35.06 | ₹8.18 | N/A |
| FREDUN.BO | ₹1,667.15 | +0.18% | 7.9B | 23.85 | ₹69.90 | +0.04% |
| BPLPHARMA.BO | ₹1,112.80 | +1.11% | 7.7B | -25.99 | -₹42.81 | +0.09% |
Stock Comparison
ZENLABS.BO vs MEDPLUS.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, MEDPLUS.BO has a market cap of 100.3B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while MEDPLUS.BO trades at ₹836.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas MEDPLUS.BO's P/E ratio is 48.53. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to MEDPLUS.BO's ROE of +0.12%. Regarding short-term risk, ZENLABS.BO is more volatile compared to MEDPLUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check MEDPLUS.BO's competition here
ZENLABS.BO vs MEDPLUS.NS Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, MEDPLUS.NS has a market cap of 100.2B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while MEDPLUS.NS trades at ₹835.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas MEDPLUS.NS's P/E ratio is 48.36. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, ZENLABS.BO is more volatile compared to MEDPLUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check MEDPLUS.NS's competition here
ZENLABS.BO vs GUJTHEM.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, GUJTHEM.BO has a market cap of 36.5B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while GUJTHEM.BO trades at ₹334.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas GUJTHEM.BO's P/E ratio is 76.59. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, ZENLABS.BO is less volatile compared to GUJTHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check GUJTHEM.BO's competition here
ZENLABS.BO vs SHUKRAPHAR.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SHUKRAPHAR.BO has a market cap of 15.7B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SHUKRAPHAR.BO trades at ₹35.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SHUKRAPHAR.BO's P/E ratio is -179.60. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, ZENLABS.BO is less volatile compared to SHUKRAPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check SHUKRAPHAR.BO's competition here
ZENLABS.BO vs KPL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, KPL.BO has a market cap of 14.6B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while KPL.BO trades at ₹1,411.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas KPL.BO's P/E ratio is 25.86. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, ZENLABS.BO is less volatile compared to KPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check KPL.BO's competition here
ZENLABS.BO vs SASTASUNDR.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SASTASUNDR.BO has a market cap of 9.1B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SASTASUNDR.BO trades at ₹287.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SASTASUNDR.BO's P/E ratio is 35.12. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, ZENLABS.BO is more volatile compared to SASTASUNDR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check SASTASUNDR.BO's competition here
ZENLABS.BO vs SASTASUNDR.NS Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SASTASUNDR.NS has a market cap of 9.1B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SASTASUNDR.NS trades at ₹286.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SASTASUNDR.NS's P/E ratio is 35.06. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, ZENLABS.BO is more volatile compared to SASTASUNDR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check SASTASUNDR.NS's competition here
ZENLABS.BO vs FREDUN.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, FREDUN.BO has a market cap of 7.9B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while FREDUN.BO trades at ₹1,667.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas FREDUN.BO's P/E ratio is 23.85. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, ZENLABS.BO is less volatile compared to FREDUN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check FREDUN.BO's competition here
ZENLABS.BO vs BPLPHARMA.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, BPLPHARMA.BO has a market cap of 7.7B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while BPLPHARMA.BO trades at ₹1,112.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas BPLPHARMA.BO's P/E ratio is -25.99. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, ZENLABS.BO is less volatile compared to BPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check BPLPHARMA.BO's competition here
ZENLABS.BO vs ANUHPHR.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, ANUHPHR.BO has a market cap of 7.4B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while ANUHPHR.BO trades at ₹73.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas ANUHPHR.BO's P/E ratio is 17.62. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, ZENLABS.BO is more volatile compared to ANUHPHR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check ANUHPHR.BO's competition here
ZENLABS.BO vs PRAVEG.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, PRAVEG.BO has a market cap of 7B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while PRAVEG.BO trades at ₹268.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas PRAVEG.BO's P/E ratio is -283.00. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, ZENLABS.BO is less volatile compared to PRAVEG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check PRAVEG.BO's competition here
ZENLABS.BO vs SGRL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SGRL.BO has a market cap of 6.5B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SGRL.BO trades at ₹506.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SGRL.BO's P/E ratio is 35.97. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, ZENLABS.BO is more volatile compared to SGRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check SGRL.BO's competition here
ZENLABS.BO vs SUDARSHAN.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SUDARSHAN.BO has a market cap of 6.5B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SUDARSHAN.BO trades at ₹26.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SUDARSHAN.BO's P/E ratio is 31.94. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SUDARSHAN.BO's ROE of +0.16%. Regarding short-term risk, ZENLABS.BO is less volatile compared to SUDARSHAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check SUDARSHAN.BO's competition here
ZENLABS.BO vs ALBERTDA.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to ALBERTDA.BO's ROE of +0.02%. Regarding short-term risk, ZENLABS.BO is less volatile compared to ALBERTDA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check ALBERTDA.BO's competition here
ZENLABS.BO vs VIKRAMTH.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, VIKRAMTH.BO has a market cap of 5B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while VIKRAMTH.BO trades at ₹158.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas VIKRAMTH.BO's P/E ratio is 14.60. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, ZENLABS.BO is less volatile compared to VIKRAMTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check VIKRAMTH.BO's competition here
ZENLABS.BO vs JENBURPH.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, JENBURPH.BO has a market cap of 4.4B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while JENBURPH.BO trades at ₹1,005.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas JENBURPH.BO's P/E ratio is 13.69. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, ZENLABS.BO is more volatile compared to JENBURPH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check JENBURPH.BO's competition here
ZENLABS.BO vs TLL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, TLL.BO has a market cap of 3B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while TLL.BO trades at ₹254.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas TLL.BO's P/E ratio is 20.43. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, ZENLABS.BO is more volatile compared to TLL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check TLL.BO's competition here
ZENLABS.BO vs ZENOTECH.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, ZENOTECH.BO has a market cap of 2.9B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while ZENOTECH.BO trades at ₹47.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas ZENOTECH.BO's P/E ratio is 85.95. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, ZENLABS.BO is more volatile compared to ZENOTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check ZENOTECH.BO's competition here
ZENLABS.BO vs GENNEX.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, GENNEX.BO has a market cap of 2.8B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while GENNEX.BO trades at ₹11.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas GENNEX.BO's P/E ratio is 15.84. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, ZENLABS.BO is more volatile compared to GENNEX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check GENNEX.BO's competition here
ZENLABS.BO vs KERALAYUR.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, KERALAYUR.BO has a market cap of 2.7B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while KERALAYUR.BO trades at ₹225.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas KERALAYUR.BO's P/E ratio is -11.50. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, ZENLABS.BO is less volatile compared to KERALAYUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check KERALAYUR.BO's competition here
ZENLABS.BO vs BDH.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, BDH.BO has a market cap of 2.5B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while BDH.BO trades at ₹428.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas BDH.BO's P/E ratio is 23.65. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, ZENLABS.BO is less volatile compared to BDH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check BDH.BO's competition here
ZENLABS.BO vs SANJIVIN.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SANJIVIN.BO has a market cap of 2.4B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SANJIVIN.BO trades at ₹194.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SANJIVIN.BO's P/E ratio is 32.63. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SANJIVIN.BO's ROE of +0.22%. Regarding short-term risk, ZENLABS.BO is less volatile compared to SANJIVIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check SANJIVIN.BO's competition here
ZENLABS.BO vs SYSCHEM.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SYSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SYSCHEM.BO trades at ₹49.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SYSCHEM.BO's P/E ratio is 33.57. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, ZENLABS.BO is less volatile compared to SYSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check SYSCHEM.BO's competition here
ZENLABS.BO vs TRANSCHEM.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, TRANSCHEM.BO has a market cap of 2.1B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while TRANSCHEM.BO trades at ₹172.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas TRANSCHEM.BO's P/E ratio is 71.97. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, ZENLABS.BO is more volatile compared to TRANSCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check TRANSCHEM.BO's competition here
ZENLABS.BO vs AMBALALSA.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, AMBALALSA.BO has a market cap of 2B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while AMBALALSA.BO trades at ₹26.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas AMBALALSA.BO's P/E ratio is 20.88. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, ZENLABS.BO is more volatile compared to AMBALALSA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check AMBALALSA.BO's competition here
ZENLABS.BO vs OXYGENTAPH.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, OXYGENTAPH.BO has a market cap of 1.9B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while OXYGENTAPH.BO trades at ₹52.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas OXYGENTAPH.BO's P/E ratio is -11.12. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to OXYGENTAPH.BO's ROE of +0.65%. Regarding short-term risk, ZENLABS.BO is less volatile compared to OXYGENTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check OXYGENTAPH.BO's competition here
ZENLABS.BO vs AUROLAB.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, AUROLAB.BO has a market cap of 1.8B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while AUROLAB.BO trades at ₹291.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas AUROLAB.BO's P/E ratio is 55.95. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, ZENLABS.BO is more volatile compared to AUROLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check AUROLAB.BO's competition here
ZENLABS.BO vs NATCAPSUQ.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, NATCAPSUQ.BO has a market cap of 1.6B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while NATCAPSUQ.BO trades at ₹160.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas NATCAPSUQ.BO's P/E ratio is -13.59. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, ZENLABS.BO is more volatile compared to NATCAPSUQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check NATCAPSUQ.BO's competition here
ZENLABS.BO vs KIMIABL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, KIMIABL.BO has a market cap of 1.6B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while KIMIABL.BO trades at ₹33.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to KIMIABL.BO's ROE of +1.10%. Regarding short-term risk, ZENLABS.BO is more volatile compared to KIMIABL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check KIMIABL.BO's competition here
ZENLABS.BO vs CORALAB.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, CORALAB.BO has a market cap of 1.5B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while CORALAB.BO trades at ₹427.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas CORALAB.BO's P/E ratio is 8.80. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, ZENLABS.BO is more volatile compared to CORALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check CORALAB.BO's competition here
ZENLABS.BO vs PARNAXLAB.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, PARNAXLAB.BO has a market cap of 1.5B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while PARNAXLAB.BO trades at ₹129.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas PARNAXLAB.BO's P/E ratio is 13.52. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, ZENLABS.BO is less volatile compared to PARNAXLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check PARNAXLAB.BO's competition here
ZENLABS.BO vs PANCHSHEEL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, PANCHSHEEL.BO has a market cap of 1.5B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while PANCHSHEEL.BO trades at ₹110.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas PANCHSHEEL.BO's P/E ratio is 12.15. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, ZENLABS.BO is more volatile compared to PANCHSHEEL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check PANCHSHEEL.BO's competition here
ZENLABS.BO vs SMRUTHIORG.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SMRUTHIORG.BO has a market cap of 1.3B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SMRUTHIORG.BO trades at ₹110.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SMRUTHIORG.BO's P/E ratio is 27.19. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, ZENLABS.BO is less volatile compared to SMRUTHIORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check SMRUTHIORG.BO's competition here
ZENLABS.BO vs PHARMAID.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, PHARMAID.BO has a market cap of 1.2B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while PHARMAID.BO trades at ₹35.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas PHARMAID.BO's P/E ratio is -9.92. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to PHARMAID.BO's ROE of -0.24%. Regarding short-term risk, ZENLABS.BO is less volatile compared to PHARMAID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check PHARMAID.BO's competition here
ZENLABS.BO vs LACTOSE.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, LACTOSE.BO has a market cap of 1.2B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while LACTOSE.BO trades at ₹97.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas LACTOSE.BO's P/E ratio is 42.00. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, ZENLABS.BO is more volatile compared to LACTOSE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check LACTOSE.BO's competition here
ZENLABS.BO vs TYCHE.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, TYCHE.BO has a market cap of 1.2B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while TYCHE.BO trades at ₹116.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas TYCHE.BO's P/E ratio is 12.23. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, ZENLABS.BO is more volatile compared to TYCHE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check TYCHE.BO's competition here
ZENLABS.BO vs DENISCHEM.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, DENISCHEM.BO has a market cap of 1.1B. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while DENISCHEM.BO trades at ₹76.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas DENISCHEM.BO's P/E ratio is 14.88. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, ZENLABS.BO is less volatile compared to DENISCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check DENISCHEM.BO's competition here
ZENLABS.BO vs MERCURYLAB.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, MERCURYLAB.BO has a market cap of 967.8M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while MERCURYLAB.BO trades at ₹806.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas MERCURYLAB.BO's P/E ratio is 20.52. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, ZENLABS.BO is more volatile compared to MERCURYLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check MERCURYLAB.BO's competition here
ZENLABS.BO vs SOURCENTRL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SOURCENTRL.BO has a market cap of 860.3M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SOURCENTRL.BO trades at ₹133.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SOURCENTRL.BO's P/E ratio is 28.93. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, ZENLABS.BO is less volatile compared to SOURCENTRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check SOURCENTRL.BO's competition here
ZENLABS.BO vs MAKERSL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, MAKERSL.BO has a market cap of 840.2M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while MAKERSL.BO trades at ₹142.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas MAKERSL.BO's P/E ratio is 69.13. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, ZENLABS.BO is less volatile compared to MAKERSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check MAKERSL.BO's competition here
ZENLABS.BO vs CONCORD.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, CONCORD.BO has a market cap of 802.6M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while CONCORD.BO trades at ₹80.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas CONCORD.BO's P/E ratio is 139.07. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, ZENLABS.BO is less volatile compared to CONCORD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check CONCORD.BO's competition here
ZENLABS.BO vs BIBCL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, BIBCL.BO has a market cap of 786.3M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while BIBCL.BO trades at ₹18.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas BIBCL.BO's P/E ratio is -4.78. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, ZENLABS.BO is more volatile compared to BIBCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check BIBCL.BO's competition here
ZENLABS.BO vs BACPHAR.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, BACPHAR.BO has a market cap of 711.6M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while BACPHAR.BO trades at ₹49.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas BACPHAR.BO's P/E ratio is 134.00. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, ZENLABS.BO is less volatile compared to BACPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check BACPHAR.BO's competition here
ZENLABS.BO vs SUNLOC.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SUNLOC.BO has a market cap of 707.1M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SUNLOC.BO trades at ₹68.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SUNLOC.BO's P/E ratio is 24.71. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, ZENLABS.BO is less volatile compared to SUNLOC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check SUNLOC.BO's competition here
ZENLABS.BO vs PHRMASI.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, PHRMASI.BO has a market cap of 696.3M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while PHRMASI.BO trades at ₹104.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas PHRMASI.BO's P/E ratio is 3.92. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, ZENLABS.BO is less volatile compared to PHRMASI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check PHRMASI.BO's competition here
ZENLABS.BO vs GODAVARI.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, GODAVARI.BO has a market cap of 616.2M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while GODAVARI.BO trades at ₹81.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas GODAVARI.BO's P/E ratio is -89.92. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, ZENLABS.BO is less volatile compared to GODAVARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check GODAVARI.BO's competition here
ZENLABS.BO vs PANJON.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, PANJON.BO has a market cap of 496.1M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while PANJON.BO trades at ₹28.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas PANJON.BO's P/E ratio is 115.60. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, ZENLABS.BO is less volatile compared to PANJON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check PANJON.BO's competition here
ZENLABS.BO vs VISTAPH.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, VISTAPH.BO has a market cap of 439.5M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while VISTAPH.BO trades at ₹7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas VISTAPH.BO's P/E ratio is -6.26. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, ZENLABS.BO is less volatile compared to VISTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check VISTAPH.BO's competition here
ZENLABS.BO vs SHELTER.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SHELTER.BO has a market cap of 433M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SHELTER.BO trades at ₹37.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SHELTER.BO's P/E ratio is 6.92. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SHELTER.BO's ROE of +0.12%. Regarding short-term risk, ZENLABS.BO is more volatile compared to SHELTER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check SHELTER.BO's competition here
ZENLABS.BO vs VEERHEALTH.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, VEERHEALTH.BO has a market cap of 399.6M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while VEERHEALTH.BO trades at ₹19.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas VEERHEALTH.BO's P/E ratio is 83.25. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, ZENLABS.BO is more volatile compared to VEERHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check VEERHEALTH.BO's competition here
ZENLABS.BO vs VRL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, VRL.BO has a market cap of 399.3M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while VRL.BO trades at ₹125.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas VRL.BO's P/E ratio is 10.68. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to VRL.BO's ROE of +0.12%. Regarding short-term risk, ZENLABS.BO is less volatile compared to VRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check VRL.BO's competition here
ZENLABS.BO vs SANDUPHQ.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SANDUPHQ.BO has a market cap of 350.2M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SANDUPHQ.BO trades at ₹36.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SANDUPHQ.BO's P/E ratio is 21.58. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, ZENLABS.BO is more volatile compared to SANDUPHQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check SANDUPHQ.BO's competition here
ZENLABS.BO vs ROOPAIND.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, ROOPAIND.BO has a market cap of 350M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while ROOPAIND.BO trades at ₹44.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas ROOPAIND.BO's P/E ratio is 18.16. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, ZENLABS.BO is more volatile compared to ROOPAIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check ROOPAIND.BO's competition here
ZENLABS.BO vs DECCAN.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, DECCAN.BO has a market cap of 327.7M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while DECCAN.BO trades at ₹13.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas DECCAN.BO's P/E ratio is 24.54. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, ZENLABS.BO is less volatile compared to DECCAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check DECCAN.BO's competition here
ZENLABS.BO vs GUJTERC.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, GUJTERC.BO has a market cap of 304.2M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while GUJTERC.BO trades at ₹41.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas GUJTERC.BO's P/E ratio is -21.93. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, ZENLABS.BO is more volatile compared to GUJTERC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check GUJTERC.BO's competition here
ZENLABS.BO vs MEDICAPQ.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, MEDICAPQ.BO has a market cap of 301M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while MEDICAPQ.BO trades at ₹24.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas MEDICAPQ.BO's P/E ratio is -5.34. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, ZENLABS.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check MEDICAPQ.BO's competition here
ZENLABS.BO vs ANG.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, ANG.BO has a market cap of 298.9M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while ANG.BO trades at ₹22.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas ANG.BO's P/E ratio is -2.45. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, ZENLABS.BO is less volatile compared to ANG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check ANG.BO's competition here
ZENLABS.BO vs CRSTCHM.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, CRSTCHM.BO has a market cap of 271.7M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while CRSTCHM.BO trades at ₹90.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas CRSTCHM.BO's P/E ratio is 13.83. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, ZENLABS.BO is less volatile compared to CRSTCHM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check CRSTCHM.BO's competition here
ZENLABS.BO vs TRIMURTHI.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to TRIMURTHI.BO's ROE of +0.04%. Regarding short-term risk, ZENLABS.BO is more volatile compared to TRIMURTHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check TRIMURTHI.BO's competition here
ZENLABS.BO vs ASRL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, ASRL.BO has a market cap of 220.6M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while ASRL.BO trades at ₹7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas ASRL.BO's P/E ratio is 12.98. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to ASRL.BO's ROE of +0.01%. Regarding short-term risk, ZENLABS.BO is less volatile compared to ASRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check ASRL.BO's competition here
ZENLABS.BO vs ISHITADR.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, ISHITADR.BO has a market cap of 212.8M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while ISHITADR.BO trades at ₹71.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas ISHITADR.BO's P/E ratio is 23.96. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to ISHITADR.BO's ROE of +0.08%. Regarding short-term risk, ZENLABS.BO is more volatile compared to ISHITADR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check ISHITADR.BO's competition here
ZENLABS.BO vs CHEMOPH.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to CHEMOPH.BO's ROE of -0.87%. Regarding short-term risk, ZENLABS.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check CHEMOPH.BO's competition here
ZENLABS.BO vs ZENITHHE.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, ZENITHHE.BO has a market cap of 175.7M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while ZENITHHE.BO trades at ₹3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas ZENITHHE.BO's P/E ratio is -327.00. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, ZENLABS.BO is less volatile compared to ZENITHHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check ZENITHHE.BO's competition here
ZENLABS.BO vs EMMESSA.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, EMMESSA.BO has a market cap of 134.7M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while EMMESSA.BO trades at ₹26.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas EMMESSA.BO's P/E ratio is 61.30. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, ZENLABS.BO is more volatile compared to EMMESSA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check EMMESSA.BO's competition here
ZENLABS.BO vs NORRIS.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, NORRIS.BO has a market cap of 127.5M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while NORRIS.BO trades at ₹12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to NORRIS.BO's ROE of +0.08%. Regarding short-term risk, ZENLABS.BO is less volatile compared to NORRIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check NORRIS.BO's competition here
ZENLABS.BO vs CHCL.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, CHCL.BO has a market cap of 125.2M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while CHCL.BO trades at ₹5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, ZENLABS.BO is more volatile compared to CHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check CHCL.BO's competition here
ZENLABS.BO vs COLINZ.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, COLINZ.BO has a market cap of 122.7M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while COLINZ.BO trades at ₹48.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas COLINZ.BO's P/E ratio is 24.85. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, ZENLABS.BO is less volatile compared to COLINZ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check COLINZ.BO's competition here
ZENLABS.BO vs PARMAX.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, PARMAX.BO has a market cap of 116M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while PARMAX.BO trades at ₹31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas PARMAX.BO's P/E ratio is -3.97. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to PARMAX.BO's ROE of +2.05%. Regarding short-term risk, ZENLABS.BO is less volatile compared to PARMAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check PARMAX.BO's competition here
ZENLABS.BO vs DESHRAK.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, DESHRAK.BO has a market cap of 113.7M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while DESHRAK.BO trades at ₹25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas DESHRAK.BO's P/E ratio is 30.90. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, ZENLABS.BO is more volatile compared to DESHRAK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check DESHRAK.BO's competition here
ZENLABS.BO vs SHAMROIN.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, SHAMROIN.BO has a market cap of 110.6M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while SHAMROIN.BO trades at ₹20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas SHAMROIN.BO's P/E ratio is -22.89. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to SHAMROIN.BO's ROE of -0.68%. Regarding short-term risk, ZENLABS.BO is more volatile compared to SHAMROIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check SHAMROIN.BO's competition here
ZENLABS.BO vs BERLDRG.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, BERLDRG.BO has a market cap of 109.9M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while BERLDRG.BO trades at ₹21.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas BERLDRG.BO's P/E ratio is 722.00. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, ZENLABS.BO is more volatile compared to BERLDRG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check BERLDRG.BO's competition here
ZENLABS.BO vs TRINITYLEA.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, TRINITYLEA.BO has a market cap of 108.1M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while TRINITYLEA.BO trades at ₹13.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas TRINITYLEA.BO's P/E ratio is -273.00. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, ZENLABS.BO is more volatile compared to TRINITYLEA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check TRINITYLEA.BO's competition here
ZENLABS.BO vs HINDBIO.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, HINDBIO.BO has a market cap of 85.4M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while HINDBIO.BO trades at ₹8.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas HINDBIO.BO's P/E ratio is 55.53. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to HINDBIO.BO's ROE of +0.17%. Regarding short-term risk, ZENLABS.BO is more volatile compared to HINDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check HINDBIO.BO's competition here
ZENLABS.BO vs VIVANZA.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, VIVANZA.BO has a market cap of 82.4M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while VIVANZA.BO trades at ₹2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas VIVANZA.BO's P/E ratio is -25.75. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, ZENLABS.BO is more volatile compared to VIVANZA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check VIVANZA.BO's competition here
ZENLABS.BO vs ADLINE.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, ADLINE.BO has a market cap of 82M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while ADLINE.BO trades at ₹14.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, ZENLABS.BO is less volatile compared to ADLINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check ADLINE.BO's competition here
ZENLABS.BO vs DECIPHER.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, DECIPHER.BO has a market cap of 80.8M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while DECIPHER.BO trades at ₹8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas DECIPHER.BO's P/E ratio is -1.00. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to DECIPHER.BO's ROE of -0.38%. Regarding short-term risk, ZENLABS.BO is less volatile compared to DECIPHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check DECIPHER.BO's competition here
ZENLABS.BO vs EVOQ.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, EVOQ.BO has a market cap of 79.4M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while EVOQ.BO trades at ₹3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas EVOQ.BO's P/E ratio is 4.49. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, ZENLABS.BO is more volatile compared to EVOQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check EVOQ.BO's competition here
ZENLABS.BO vs GANGAPHARM.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while GANGAPHARM.BO trades at ₹12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, ZENLABS.BO is more volatile compared to GANGAPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check GANGAPHARM.BO's competition here
ZENLABS.BO vs KOBO.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, KOBO.BO has a market cap of 65.5M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while KOBO.BO trades at ₹2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas KOBO.BO's P/E ratio is -1.30. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, ZENLABS.BO is less volatile compared to KOBO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check KOBO.BO's competition here
ZENLABS.BO vs TIAANC.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, TIAANC.BO has a market cap of 63.2M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while TIAANC.BO trades at ₹6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas TIAANC.BO's P/E ratio is -61.50. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, ZENLABS.BO is less volatile compared to TIAANC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check TIAANC.BO's competition here
ZENLABS.BO vs PATIDAR.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, PATIDAR.BO has a market cap of 52M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while PATIDAR.BO trades at ₹9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas PATIDAR.BO's P/E ratio is -19.29. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, ZENLABS.BO is more volatile compared to PATIDAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check PATIDAR.BO's competition here
ZENLABS.BO vs WELCURE.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, WELCURE.BO has a market cap of 39.3M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while WELCURE.BO trades at ₹0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas WELCURE.BO's P/E ratio is 1.21. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, ZENLABS.BO is less volatile compared to WELCURE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check WELCURE.BO's competition here
ZENLABS.BO vs TMTIND-B1.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, TMTIND-B1.BO has a market cap of 34.5M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while TMTIND-B1.BO trades at ₹6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas TMTIND-B1.BO's P/E ratio is -7.83. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, ZENLABS.BO is more volatile compared to TMTIND-B1.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ZENLABS.BO.Check TMTIND-B1.BO's competition here
ZENLABS.BO vs FABINO.BO Comparison February 2026
ZENLABS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENLABS.BO stands at 137.1M. In comparison, FABINO.BO has a market cap of 27.5M. Regarding current trading prices, ZENLABS.BO is priced at ₹21.06, while FABINO.BO trades at ₹13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENLABS.BO currently has a P/E ratio of -7.42, whereas FABINO.BO's P/E ratio is -17.95. In terms of profitability, ZENLABS.BO's ROE is -0.18%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, ZENLABS.BO is less volatile compared to FABINO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ZENLABS.BO.Check FABINO.BO's competition here